Tubulis Reports the US FDA’s Fast Track Designation of TUB-040 to Treat Ovarian Cancer
Shots:
- The US FDA has granted FTD to the company’s TUB-040, based on P5 technology, to treat Pt-resistant ovarian cancer. The preclinical models, incl. ovarian cancer, depicted its effective & durable responses
- TUB-040 monotx. is being assessed in the P-I/IIa (NAPISTAR 1-01) trial for its safety with P-I finding the MTD or the identified dose for optimization as well as P-IIa designed for dose optimization & preliminary efficacy across the US, UK, Spain, Belgium & Germany
- TUB-040 is an ADC that comprises an IgG1 antibody linked with Topoisomerase I inhibitor Exatecan via a cleavable linker system. It targets Napi2b which is highly expressed in ovarian cancer and lung adenocarcinoma
Ref: Tubulis | Image: Tubulis
Related News:- Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-aa
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
